This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Synthon Pharmaceuticals, Inc.
Drug Names(s): Full-Length Recombinant Plasmin
Description: BLX-155 is a recombinant form of plasmin, a naturally occurring human enzyme responsible for dissolving fibrin, a key component of blood clots. As a direct-acting thrombolytic, researchers believe BLX-155 has the potential to provide efficacy and safety advantages over products that dissolve blood clots indirectly by activating the enzyme plasminogen, an inactive form of plasmin, including tissue-type plasminogen activators, or t-PAs, which are the current standard of care.
Deal Structure: BLX-155 was originally developed by Biolex using the LEX system.
In April 2012, Synthon announced its acquisition of key assets of Biolex Therapeutics. The deal comprises the LEX System and two biological drug candidates that capitalize on the benefits of the LEX System. The deal excludes Locteron and related assets which have been retained by Biolex.
Additional information available to subscribers only: